Related Experiment Video
Updated: Jan 29, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing
Yuki Yoshino1, Shino Endo1, Zhenghao Chen1
1Department of Cancer Biology, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai, 980-8575, Japan.
Abstract:
Homologous recombination (HR) contributes to the repair of DNA double-strand breaks (DSBs) and inter-strand crosslinks. The HR activity in cancer cells can be used to predict their sensitivity to DNA-damaging agents that cause these damages. To evaluate HR activity, we developed a system called Assay for Site-specific HR Activity (ASHRA), in which cells are transiently transfected with an expression vector for CRISPR/Cas9 and a HR donor sequence containing a marker gene. DSBs are created by Cas9 and then repaired by HR using donor vector sequences homologous to the target gene. The level of genomic integration of the marker gene is quantified by Western blotting, flowcytometry, or quantitative PCR (qPCR). ASHRA detected HR deficiency caused by BRCA1, BARD1, or RAD51 knockdown or introduction of BRCA1 variants. The influence of BRCA1 variants on HR, as determined by qPCR, was consistent with the chemosensitivities of the transfected cells. The qPCR format of ASHRA could measure HR activity in both transcribed and un-transcribed regions. Knockdown of BRCA1 nor BARD1 did not affect HR activity in a transcriptionally inactive site. ASHRA can evaluate HR activity and will be useful for predicting sensitivity to chemotherapy, screening drugs that affect HR, and investigating the mechanisms of HR.
Insights
We developed the Assay for Site-specific HR Activity (ASHRA) to measure homologous recombination (HR) DNA repair. ASHRA accurately predicts cancer cell sensitivity to chemotherapy by evaluating HR activity.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Homologous recombination (HR) is crucial for repairing DNA double-strand breaks (DSBs) and inter-strand crosslinks.
- HR activity in cancer cells correlates with sensitivity to DNA-damaging chemotherapeutic agents.
- Accurate measurement of HR activity is vital for personalized cancer treatment and drug development.
Purpose of the Study:
- To develop and validate a novel system, Assay for Site-specific HR Activity (ASHRA), for quantifying cellular HR activity.
- To assess the utility of ASHRA in detecting HR deficiencies and predicting chemosensitivity.
- To investigate the influence of specific genes and variants on HR activity in different genomic contexts.
Main Methods:
- Transient transfection of cells with CRISPR/Cas9 and a HR donor vector containing a marker gene.
- Induction of DSBs by Cas9, followed by repair via HR using the donor sequence.
- Quantification of marker gene genomic integration using Western blotting, flow cytometry, or quantitative PCR (qPCR).
Main Results:
- ASHRA successfully detected HR deficiency resulting from knockdown of BRCA1, BARD1, or RAD51, and from BRCA1 variants.
- qPCR-based ASHRA results for BRCA1 variants correlated with the chemosensitivity of transfected cells.
- ASHRA's qPCR format demonstrated the ability to measure HR activity in both transcribed and un-transcribed genomic regions, with no HR activity observed in transcriptionally inactive sites upon BRCA1 or BARD1 knockdown.
Conclusions:
- ASHRA is a robust system for evaluating cellular HR activity.
- ASHRA can predict patient sensitivity to chemotherapy, aiding in personalized treatment strategies.
- The developed assay is valuable for screening HR-modulating drugs and advancing the understanding of HR mechanisms.
Related Concept Videos
Homologous Recombination
Homologous Recombination
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Cell Specific Gene Expression
Cell Specific Gene Expression
RNA Editing

